Gain Therapeutics, Inc. (GANX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Gain Therapeutics, Inc. (GANX)
Company Performance

Current Price

as of Oct 18, 2024

$2.70

P/E Ratio

N/A

Market Cap

$68.95M

Description

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Metrics

Overview

  • HQBethesda, MD
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerGANX
  • Price$2.7-2.53%

Trading Information

  • Market Cap$68.95M
  • Float94.91%
  • Average Daily Volume (1m)455,087
  • Average Daily Volume (3m)393,470
  • EPS-$1.31

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$8.14M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$8.16M
  • EV$8.47M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B5.77
Documents
SEC Filings
8-K (2024-10-21)
8-K (2024-10-08)
8-K (2024-09-06)
8-K (2024-08-08)
8-K (2024-07-12)
8-K (2024-07-09)
8-K (2024-06-28)
8-K (2024-06-25)
8-K (2024-06-14)
8-K (2024-05-14)
8-K (2024-04-08)
8-K (2024-03-26)
8-K (2024-02-22)
8-K (2024-01-31)
8-K (2023-11-22)
8-K (2023-11-17)
8-K (2023-11-14)
8-K (2023-08-10)
8-K (2023-06-26)
8-K (2023-05-12)
8-K (2023-04-28)
8-K (2023-04-12)
8-K (2023-03-23)
10-Q (2024-08-08)
10-Q (2024-05-14)
10-Q (2023-11-14)
10-Q (2023-08-10)
10-Q (2023-05-12)
10-K (2024-03-26)
10-K (2023-03-23)
Factset
Factset Business Description
Factset Street Account
Gain Therapeutics reports Q3 EPS ($0.37) vs FactSet ($0.45) [5 est, ($0.51)-(0.38)] ($2.79, 0.00) (2023-11-14T12:10:29Z)
Gain Therapeutics notes publication of preclinical data showing restoration of enzymatic function with novel allosteric regulators in GM1 gangliosidosis model ($2.14, 0.00) (2023-12-01T13:04:11Z)
Gain Therapeutics discloses termination of controlled equity offering sales agreement with Cantor Fitzgerald - 8-K ($2.70, 0.00) (2023-11-17T21:30:23Z)
Gain Therapeutics announces pricing of $9.4M public offering and concurrent private placement of common stock and warrants through Newbridge Securities ($2.72, 0.00) (2023-11-21T13:57:09Z)